- industrial grade(1)
-
API(75)
- Other Medicine(5)
- Digestive System Medication(2)
- Vitamins(2)
- Drugs that regulate endocrine function(3)
- Blood System Medication(1)
- Analgesic(1)
- Circulatory System Medication(2)
- Antimalarial(1)
- Anesthetic(10)
- Nervous System Medication(5)
- Anti-infective drugs(5)
- Antineoplastic Medicine(5)
- Antipyretic Analgesics(1)
- Antiparasitic Drugs(5)
- Organic Compounds(429)
- Others(64)
- 2-Bromo-1-Phenylpentan-1-One(13)
- Pharmaceutical raw material(105)
- Chemical intermediate(9)
- Oxiranecarboxylicacid(1)
- Organic Chemistry(3)
- polypeptide(5)
- Steroid(36)
- Inorganic chemistry(3)
- Product Catalog >API>Antiparasitic drugs>Antimalarial drugs>Quinine hcl(1)
- Chemical Reagents(18)
- Diethyl(phenylacetyl)malonate(1)
- 13(13)
- Peptide Raw Powder(40)
- SRAMS(20)
- 11(72)
Wingroup Pharmaceutial Co.Ltd | |
---|---|
Country: | China |
Tel: | +86-18062075862 |
Fax: | +86-27-87819568 |
E-mail: | admin@whwingroup.com |
WhatsApp: | Chat Now! |
Skype: | Chat Now! |
Wuhan wingroup Pharmaceutical Co.,Ltd located in Wuhan, Hubei Province, is a company dedicated to R & D,production and sales of organic compounds, pharmaceutical intermediates, chemical raw materials. The company has a long term cooperation with Wuhan Research Institute and other universities. It is a pharmaceutical enterprise oriented by the global pharmaceutical market demand and integrating the research and development, industrialization and market operation of innovative drugs. At present, the company has submitted 10 domestic patents and one PCT patent (International Patent); And obtained the authorization of 7 invention patents. The company has strong technical strength, advanced equipme-nt, strict quality management system and high-quality after-sales service.
Over the years, our products have been widely sold to many countries and regions that we have established stable relations of cooperation with the traders and end users all around the world and have become a solid bridge among the suppliers, traders and end users.